World Alzheimer's Day 2021: The Power of Knowledge

World Alzheimer's Day is an international campaign organised by Alzheimer's Disease International to raise awareness and highlight issues faced by people affected by dementia. It takes place every year on September 21st and is the focus of World Alzheimer's Month.

Dementia is one of the biggest challenges we face, with nearly 50 million people living with dementia worldwide. Yet 2 out of every 3 people globally believe there is little or no understanding of dementia in their countries.The impact of World Alzheimer's Month is growing, but the stigmatisation and misinformation that surrounds dementia remains a global problem. To tackle this challenge, we need to collaborate and share best practice with one another.

In support of this year’s theme – ‘Know dementia, know Alzheimer's’ - Elsevier presents a curated, open access collection of over 70 journal articles and book chapters focused on shining a light on the warning signs of dementia and the importance of a timely diagnosis.

Elsevier,

EBioMedicine, Volume 57, 2020, 102834

This is the first study to assess the diagnostic performance and specificity of a saliva-based single biomarker to detect prodromal Alzheimer's disease (AD) and AD dementia based on their amyloid-PET biomarker profile.
Elsevier,

EBioMedicine, Volume 67, May 2021

In this study, lactoferrin in CSF and saliva was investigated as a diagnostic biomarker for AD and other neurodegenerative dementias in a consecutive, mixed memory clinic cohort.
Elsevier,

EClinicalMedicine, Volume 32, February 2021

This cohort study looked at how sleep disturbances may increase risks of Alzheimer's disease (AD) and other dementias.
Elsevier,

The Lancet Healthy Longevity, Volume 1, December 2020

This study is the first, large, prospective cohort study showing an integral or a bidirectional relation between circadian aging and Alzheimer's progression.
Elsevier,

EClinicalMedicine, Volume 28, November 2020

A study to assess the use of classification methods to predict future onset of Alzheimer's disease.
Elsevier,

EBioMedicine, Volume 59, September 2020

This is the first proof of concept study that genotype and mechanism specific treatment is feasible in AD.
Elsevier,

The Lancet Neurology, Volume 19, September 2020

This Editorial discusses how Latin America takes centre stage in dementia prevention.
Elsevier,

EBioMedicine, Volume 59, September 2020

This is the first study to examine the gut fungal microbiome (mycobiome) in patients with mild cognitive impairment MCI while also evaluating the effect of MMKD on gut mycobiome in association with cerebrospinal fluid (CSF) AD biomarkers and gut fungal-bacterial co-occurrence network.
Elsevier,

EBioMedicine, Volume 58, August 2020

This study explores the relationships between microglia, perineuronal nets, and amyloid plaques in Alzheimer's disease model and human brains through immunohistochemical analysis.
Elsevier,

EClinicalMedicine, Volume 38, 2021, 100988

This cross-sectional study examined whether levels of soluble Aβ42 are higher in amyloid-positive normal cognition (NC) individuals compared to mild cognitive impairment (MCI) and Alzheimer's disease.

Pages